Chemoinformatic analysis of NCI preclinical tumor data: Evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors

Journal of Chemical Information and Modeling

Volumn 47, Issue 4, 2007, Pages 1414-1427

  Wallqvist, Anders ^b   Huang, Ruili ^a   Covell, David G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DATA REDUCTION; DRUG THERAPY; GRAFTING (CHEMICAL); MATHEMATICAL MODELS; TUMORS;

CHEMOINFORMATIC; WEIGHT REDUCTION (TW); XENOGRAFT DATA;

CHEMICAL ENGINEERING;

ANTINEOPLASTIC AGENT;

ANIMAL; ARTICLE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HEALTH CARE ORGANIZATION; MOUSE; UNITED STATES; VALIDATION STUDY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; MICE; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS; UNITED STATES;

EID: 34547691015     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci700132u     Document Type: Article

References (44)

1. Martin, Y. C.; Kofron, J. L.; Traphagen, L. M. Do structurally similar molecules have similar biological activity? J. Med. Chem. 2002, 45 (19), 4350-8.
2. Willett, P. Similarity-based approaches to virtual screening. Biochem. Soc. Trans. 2003, 31 (Pt 3), 603-6.
3. Voigt, J. H.; Bienfait, B.; Wang, S.; Nicklaus, M. C. Comparison of the NCI Open Database with Seven Large Chemical Structural Databases. J. Chem. Inf. Comput. Sci. 2001, 41, 702-712.
4. Wallqvist, A.; Huang, R.; Thanki, N.; Covell, D. G. Evaluating chemical structure similarity as an indicator of cellular growth inhibition. J. Chem. Inf. Model. 2006, 46 (1), 430-7.
5. Maggiora, G. M. On outliers and activity cliffs-why QSAR often disappoints. J. Chem. Inf. Model. 2006, 46 (4), 1535.
6. Kelly, D. E.; Clark, A. Modern approaches to drug discovery and design: setting the scene. Biochem. Soc. Trans. 2003, 31 (2), 428.
7. Jonsdottir, S. O.; Jorgensen, F. S.; Brunak, S. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates. Bioinformatics 2005, 21 (10), 2145-60.
8. Brown, F. Editorial opinion: chemoinformatics-a ten year update. Curr. Opin. Drug Discovery Dev. 2005, 8 (3), 298-302.
9. Oprea, T. I. Chemoinformatics in Drug Discovery; Wiley-VCH: Weinheim, 2005; Vol. 23.
10. Oprea, T. I.; Allu, T. K.; Fara, D. C.; Rad, R. F.; Ostopovici, L.; Bologa, C. G. Lead-like, drug-like or "Pub-like": how different are they? J. Comput-Aided Mol. Des. 2007, 21 (1-3), 113-9.
11. Gagna, C. E.; Winokur, D.; Lambert, C. W. Cell biology, chemogenomics and chemoproteomics. Cell Biol. Int. 2004, 28 (11), 755-64.
12. Kerbel, R. S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2003, 2 (4 Suppl 1), S134-9.
13. Sausville, E. A.; Burger, A. M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006, 66 (7), 3351-4, discussion 3354.
14. Voskoglou-Nomikos, T.; Pater, J. L.; Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 2003, 9 (11), 4227-39.
15. Teicher, B. A. Tumor models for efficacy determination. Mol. Cancer Ther. 2006, 5 (10), 2435-43.
16. Rogatko, A.; Babb, J. S.; Tighiouart, M.; Khuri, F. R.; Hudes, G. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin. Cancer Res. 2005, 11 (15), 5342-6.
17. Sausville, E. A. Optimizing target selection and development strategy in cancer treatment: the next wave. Curr. Med. Chem. Anticancer Agents 2004, 4 (5), 445-7.
18. Suggitt, M.; Bibby, M. C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res. 2005, 11 (3), 971-81.
19. Hariparsad, N.; Sane, R. S.; Strom, S. C.; Desai, P. B. In vitro methods in human drug biotransformation research: implications for cancer chemotherapy. Toxicol, in Vitro 2006, 20 (2), 135-53.
20. Schrag, D.; Garewal, H. S.; Burstein, H. J.; Samson, D. J.; Von Hoff, D. D.; Somerfield, M. R. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 2004, 22 (17), 3631-8.
21. Berger, D. P.; Henss, H.; Winterhalter, B. R.; Fiebig, H. H. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening. Ann. Oncol. 1990, 1 (5), 333-41.
22. Fiebig, H. H.; Maier, A.; Burger, A. M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 2004, 40 (6), 802-20.
23. Langdon, S. P.; Hendriks, H. R.; Braakhuis, B. J.; Pratesi, G.; Berger, D. P.; Fodstad, O.; Fiebig, H. H.; Boven, E. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann. Oncol. 1994, 5 (5), 415-22.
24. Gutmann, D. H.; Hunter-Schaedle, K.; Shannon, K. M. Harnessing preclinical mouse models to inform human clinical cancer trials. J. Clin. Invest. 2006, 116 (4), 847-52.
25. Shoemaker, R. H.; Wolpert-DeFilippes, M. K.; Kern, D. H.; Lieber, M. M.; Makuch, R. W.; Melnick, N. R.; Miller, W. T.; Salmon, S. E.; Simon, R. M.; Venditti, J. M.; et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res. 1985, 45 (5), 2145-53.
26. Marsh, J. C.; Shoemaker, R. H.; Salmon, S. E.; Kern, D. H.; Venditti, J. M. Relationship between in vitro tumor stem cell assay and in vivo antitumor activity using the P388 leukemia. Int. J. Cell Cloning 1988, 6 (1), 60-8.
27. Goldin, A.; Johnson, R. K.; Venditti, J. M. Usefulness and limitations of murine tumor models for the identification of new antitumor agents. Antibiot. Chemother. 1980, 28, 1-7.
28. Johnson, J. I.; Decker, S.; Zaharevitz, D.; Rubinstein, L. V.; Venditti, J. M.; Schepartz, S.; Kalyandrug, S.; Christian, M.; Arbuck, S.; Hollingshead, M.; Sausville, E. A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 2001, 84 (10), 1424-31.
29. Decker, S.; Hollingshead, M.; Bonomi, C. A.; Carter, J. P.; Sausville, E. A. The hollow fibre model in cancer drug screening: the NCI experience. Eur. J. Cancer 2004, 40 (6), 821-6.
30. Rabow, A. A.; Shoemaker, R. H.; Sausville, E. A.; Covell, D. G. Mining the National Cancer Institute's tumor-screening database: Identification of compounds with similar cellular activities. J. Med. Chem. 2002, 45, 818-840.
31. Covell, D. G.; Wallqvist, A.; Huang, R. L.; Thanki, N.; Rabow, A. A.; Lu, X. J. Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small-molecule screening and structural databases. Proteins: Struct. Funct. Bioinformatics 2005, 59 (3), 403-433.
32. Huang, R.; Wallqvist, A.; Thanki, N.; Covell, D. G. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. Pharmacogenomics J. 2005, 5 (6), 381-99.
33. Huang, R.; Wallqvist, A.; Covell, D. G. Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen. Genomics 2005.
34. Wheeler, D. L.; Barrett, T.; Benson, D. A.; Bryant, S. H.; Canese, K.; Chetvernin, V.; Church, D. M.; DiCuccio, M.; Edgar, R.; Federhen, S.; Geer, L. Y.; Helmberg, W.; Kapustin, Y.; Kenton, D. L.; Khovayko, O.; Lipman, D. J.; Madden, T. L.; Maglott, D. R.; Ostell, J.; Pruitt, K. D.; Schuler, G. D.; Schriml, L. M.; Sequeira, E.; Sherry, S. T.; Sirotkin, K.; Souvorov, A.; Starchenko, G.; Suzek, T. O.; Tatusov, R.; Tatusova, T. A.; Wagner, L.; Yaschenko, E. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2006, 34 (database issue), D173-80.
35. Huang, R. L.; Wallqvist, A.; Covell, D. G. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. Biochem. Pharmacol. 2005, 69 (7), 1009-1039.
36. Raynaud-Le Grandic, S.; Fourneau, C.; Laurens, A.; Bories, C.; Hocquemiller, R.; Loiseau, P. M. In vitro antileishmanial activity of acetogenins from Annonaceae. Biomed. Pharmacother. 2004, 58 (6-7), 388-92.
37. Bild, A. H.; Yao, G.; Chang, J. T.; Wang, Q.; Potti, A.; Chasse, D.; Joshi, M. B.; Harpole, D.; Lancaster, J. M.; Berchuck, A.; Olson, J. A., Jr.; Marks, J. R.; Dressman, H. K.; West, M.; Nevins, J. R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439 (7074), 353-7.
38. Dopazo, J. Functional interpretation of microarray experiments. OMICS 2006, 10 (3), 398-410.
39. Curtis, R. K.; Oresic, M.; Vidal-Puig, A. Pathways to the analysis of microarray data. Trends Biotechnol. 2005, 23 (8), 429-35.
40. Matthews, E. J.; Kruhlak, N. L.; Weaver, J. L.; Benz, R. D.; Contrera, J. F. Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Curr. Drug Discovery Technol. 2004, J (4). 243-54.
41. Matthews. E. J.; Kruhlak, N. L.; Benz, R. D.; Contrera, J. F. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. Curr. Drug Discovery Technol. 2004, 1(1), 61-76.
42. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83 (11), 757-66.
43. Keskin, O.; Bahar, I.; Jernigan, R. L.; Beutler, J. A.; Shoemaker, R. H.; Sausville, E. A.; Covell, D. G. Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure. Anticancer Drug Des. 2000, 15 (2), 79-98.
44. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81 (14), 1088-92.